Equity Profile

BLCO

Bausch + Lomb Corporation

Health CareHealth Care Supplies$5.6B

Apr29Wed

Post-Earnings Recap

ReportedQ1-2026Pre-Market6:58 AM EDT

Bausch + Lomb Misses on EPS, Stock Down 1.59%

Metric	Actual	Expected	Surprise
EPS	$0.05	$0.05	-10.71%
Revenue	N/A	$1.2B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Bausch + Lomb Misses on EPS, Stock Down 1.59%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.05	$0.05	-10.71%
Revenue	N/A	$1.2B	N/A

Management Commentary

Tone: Defensive

Management expressed concerns about the current market conditions impacting performance. They emphasized a commitment to improving operational efficiency.

We are navigating a challenging market environment.

Our focus remains on operational efficiency and cost management.

What It Means

Bausch + Lomb's earnings report shows a slight miss on EPS expectations, which contributed to a 1.59% drop in stock price. The lack of revenue data and forward guidance may raise concerns among investors about the company's future performance. Management's cautious tone suggests they are aware of the challenges ahead and are focusing on internal efficiencies.

Company Snapshot

Bausch + Lomb Corporation (BLCO) operates in the health care sector, focusing on eye health products and surgical devices. With a market cap of $6 billion, the company plays a significant role in the growing demand for eye care solutions as the global population ages.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and this quarter's consensus is particularly low, suggesting cautious expectations.

$0.05

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$1.2B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-75.76%

Avg Stock Reaction

-2.86%

Last Quarter Recap

In Q4 2025, Bausch + Lomb reported an EPS of $0.32, slightly missing the estimate of $0.35. The stock reacted negatively, declining by 0.34% the next day.

Management Promises & Guidance

Focus on improving product offerings in eye health.
Commitment to cost management and efficiency improvements.
Plans to enhance market penetration in emerging regions.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Bausch + Lomb's upcoming earnings, with a consensus EPS of $0.05 and revenue expectations at $1.2 billion. The stock's recent performance has been mixed, leading to uncertainty.

Bull Case

If the company can exceed EPS expectations and show strong revenue growth, it could signal a turnaround in performance, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet even the low expectations, it could indicate deeper issues, leading to a significant decline in stock price.

Key Metrics to Watch

EPS

$0.05

Earnings per share is a key indicator of profitability, and this quarter's consensus is particularly low, suggesting cautious expectations.

Revenue

$1.2B

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.05?

A beat on EPS could indicate stronger profitability and boost investor sentiment, while a miss could raise concerns about the company's financial health.

What are the revenue figures compared to the expected $1.2 billion?

Revenue performance will be crucial in assessing market demand for Bausch + Lomb's products and overall business growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Bausch + Lomb's potential for revenue growth driven by new product launches and market expansion.

Supporting Evidence

The company's recent focus on cost management could lead to better-than-expected margins.

Options pricing suggests a higher volatility expectation than historical performance, indicating potential for a surprise.

The strong demand for eye care products in aging populations may not be fully reflected in current estimates.

Key Risk

If revenue exceeds $1.3 billion, it could challenge the current bearish sentiment and shift market perceptions.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Bausch + Lomb can overcome its recent earnings challenges and demonstrate growth in a competitive landscape.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.02 would confirm the bear case, suggesting ongoing struggles in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±14.53%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±40.7% while BLCO has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.9%

30d HV

34.7%

Calls (14K)P/C Ratio: 2.75Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bausch + Lomb beats expectations, history suggests the stock could see a modest increase, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss on earnings could lead to a significant decline, with historical patterns indicating an average drop of around 5.19%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their expected impact on revenue.
2Any commentary on cost management strategies and their effectiveness.
3Insights into market conditions and demand trends in the eye care sector.
4Management's outlook on growth in emerging markets.
5Details on any changes in competitive landscape affecting the business.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and this quarter's consensus is particularly low, suggesting cautious expectations.

$0.05

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$1.2B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-75.76%

Avg Stock Reaction

-2.86%

Last Quarter Recap

In Q4 2025, Bausch + Lomb reported an EPS of $0.32, slightly missing the estimate of $0.35. The stock reacted negatively, declining by 0.34% the next day.

Management Promises & Guidance

Focus on improving product offerings in eye health.
Commitment to cost management and efficiency improvements.
Plans to enhance market penetration in emerging regions.

Expectations

Wall Street Expectations

Bull Case

If the company can exceed EPS expectations and show strong revenue growth, it could signal a turnaround in performance, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet even the low expectations, it could indicate deeper issues, leading to a significant decline in stock price.

Key Metrics to Watch

EPS

$0.05

Earnings per share is a key indicator of profitability, and this quarter's consensus is particularly low, suggesting cautious expectations.

Revenue

$1.2B

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.05?

A beat on EPS could indicate stronger profitability and boost investor sentiment, while a miss could raise concerns about the company's financial health.

What are the revenue figures compared to the expected $1.2 billion?

Revenue performance will be crucial in assessing market demand for Bausch + Lomb's products and overall business growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Bausch + Lomb's potential for revenue growth driven by new product launches and market expansion.

Supporting Evidence

The company's recent focus on cost management could lead to better-than-expected margins.

Options pricing suggests a higher volatility expectation than historical performance, indicating potential for a surprise.

The strong demand for eye care products in aging populations may not be fully reflected in current estimates.

Key Risk

If revenue exceeds $1.3 billion, it could challenge the current bearish sentiment and shift market perceptions.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Bausch + Lomb can overcome its recent earnings challenges and demonstrate growth in a competitive landscape.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.02 would confirm the bear case, suggesting ongoing struggles in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±14.53%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±40.7% while BLCO has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.9%

30d HV

34.7%

Calls (14K)P/C Ratio: 2.75Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bausch + Lomb beats expectations, history suggests the stock could see a modest increase, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss on earnings could lead to a significant decline, with historical patterns indicating an average drop of around 5.19%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their expected impact on revenue.
2Any commentary on cost management strategies and their effectiveness.
3Insights into market conditions and demand trends in the eye care sector.
4Management's outlook on growth in emerging markets.
5Details on any changes in competitive landscape affecting the business.